Literature DB >> 19852031

Inflammatory myofibroblastic tumors in childhood: a report from the Italian Cooperative Group studies.

Rita Alaggio1, Giovanni Cecchetto, Gianni Bisogno, Claudio Gambini, Maria Luisa Calabrò, Alessandro Inserra, Renata Boldrini, Gian Luca De Salvo, Emanuele S G d'Amore, Patrizia Dall'igna.   

Abstract

BACKGROUND: Inflammatory myofibroblastic tumors (IMTs) are myofibroblastic lesions with unpredictable biologic behavior that occur at a young age. For this report, the authors investigated clinicopathologic features in a series of pediatric IMTs. The objective of the study was to identify morphologic or immunohistochemical prognostic markers and the possible pathogenic role of human herpes virus 8 (HHV-8).
METHODS: Twenty-six patients were observed over a period of 18 years. Clinical/histologic data were reviewed, and immunohistochemical/molecular studies were performed.
RESULTS: Patients ages 8-216 months (median age, 60 months) presented with tumors of the lung-bronchus (8 patients), abdomen (17 patients), and thoracic wall (1 patient). Twenty-one patients underwent complete excision, and microscopic or macroscopic residual disease was present in 5 of those patients. Chemotherapy was received by 5 patients. After a median follow-up of 6.6 years, 24 patients were in complete remission, and 2 patients had died of disease. Local recurrences were observed in 6 patients (including 4 recurrences that occurred after a complete excision). Cytologic atypia, low inflammatory infiltrate, and a rich myxoid pattern were detected in patients who had recurrent disease or a poor prognosis. Anaplastic lymphoma kinase (ALK) was positive in 7 patients (including 2 patients with recurrent disease). No correlation between clusterin expression and prognosis was demonstrated. HHV-8 was identified in 1 pulmonary IMT.
CONCLUSIONS: IMTs are locally aggressive lesions. In this series, the local recurrence rate was 23%, and the 5-year and 10-year event-free survival rates were 87.4% and 72.8%, respectively. The results indicated that the treatment of choice is a complete, nonmutilating excision; chemotherapy may be given to patients who have microscopic or macroscopic residual disease, although the results are controversial; cytologic atypia and positive ALK status are more frequent in aggressive tumors, whereas metastatic tumors are negative for ALK; and HHV8 is not involved in the pathogenesis of IMT. Copyright 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19852031     DOI: 10.1002/cncr.24684

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Whether inflammatory myofibroblastic tumor of the thigh relapses after surgical excision?

Authors:  Hao Liu; Jun Lin; Peng Yang; Hao Shen; Huilin Yang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  In Reply.

Authors:  Silvia Stacchiotti; Giacomo Giulio Baldi; Paolo Giovanni Casali
Journal:  Oncologist       Date:  2020-10-01

3.  Inflammatory myofibroblastic tumours of the maxillary sinus: A brief clinical report and review of the literature.

Authors:  As Murthy; S Albert; C Klonk
Journal:  Plast Surg (Oakv)       Date:  2014       Impact factor: 0.947

4.  Computed tomography appearance of inflammatory myofibroblastic tumor in the abdomen: CT features and pathologic correlation.

Authors:  Bo Liu; Junlong Xu; Jiaxin Wang; Hongguang Fan; Xuan Ang; Wenming Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.

Authors:  Giacomo Giulio Baldi; Mehdi Brahmi; Salvatore Lo Vullo; Elena Cojocaru; Olivier Mir; Michela Casanova; Bruno Vincenzi; Tommaso Martino De Pas; Giovanni Grignani; Maria Abbondanza Pantaleo; Jean Yves Blay; Robin Lewis Jones; Axel Le Cesne; Anna Maria Frezza; Alessandro Gronchi; Paola Collini; Angelo Paolo Dei Tos; Carlo Morosi; Luigi Mariani; Paolo Giovanni Casali; Silvia Stacchiotti
Journal:  Oncologist       Date:  2020-07-12

6.  Omental mesenteric myxoid hamartoma, a subtype of inflammatory myofibroblastic tumor? Considerations based on the histopathological evaluation of four cases.

Authors:  K Ludwig; R Alaggio; P Dall'Igna; E Lazzari; E S G d'Amore; P M Chou
Journal:  Virchows Arch       Date:  2015-09-19       Impact factor: 4.064

7.  Inflammatory myofibroblastic tumor of the colon with an unusual presentation of intestinal intussusception.

Authors:  Yeliz Çağan Appak; Gülseren Evirgen Sahin; Semin Ayhan; Can Taneli; Erhun Kasırga
Journal:  European J Pediatr Surg Rep       Date:  2014-04-04

Review 8.  Update of pediatric soft tissue tumors with review of conventional MRI appearance-part 1: tumor-like lesions, adipocytic tumors, fibroblastic and myofibroblastic tumors, and perivascular tumors.

Authors:  Jack Porrino; Khalid Al-Dasuqi; Lina Irshaid; Annie Wang; Kimia Kani; Andrew Haims; Ezekiel Maloney
Journal:  Skeletal Radiol       Date:  2021-06-30       Impact factor: 2.199

9.  Pathology of gastrointestinal stromal tumors.

Authors:  Wai Chin Foo; Bernadette Liegl-Atzwanger; Alexander J Lazar
Journal:  Clin Med Insights Pathol       Date:  2012-07-17

10.  Inflammatory Myofibroblastic Tumor Presenting with Diabetes Insipidus in an Eight-Year-Old Boy: A Case Report.

Authors:  Erkan Sarı; Erman Ataş; Engin Burak Bulut; Sebahattin Sarı; Onur Akın; Mehmet Saldır; Yıldırım Karslıoğlu; Ediz Yeşilkaya
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.